The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing — atom by atom — both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS.\ You will be hooked from start to finish,...
Search in google:
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing — atom by atom — both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS.You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS. Publishers Weekly A startup pharmaceutical company is the focus of this intriguing look at the nexus of biotechnology and high finance; features a new epilogue by the author. (Mar.)
\ Publishers Weekly - Publisher's Weekly\ A startup pharmaceutical company is the focus of this intriguing look at the nexus of biotechnology and high finance; features a new epilogue by the author. (Mar.)\ \
